We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+20.34%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$4.16B
AUM Growth
+$284M
Cap. Flow
+$60M
Cap. Flow %
1.44%
Top 10 Hldgs %
34.47%
Holding
129
New
1
Increased
41
Reduced
24
Closed
9

Top Buys

Rank Stock Value
1
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$29.3M
2
RXDX
Prometheus Biosciences, Inc. Common Stock
RXDX
+$25M
3
BAX icon
Baxter International
BAX
+$21.2M
4
BPMC
Blueprint Medicines
BPMC
+$16.9M
5
IRON icon
Disc Medicine
IRON
+$16.9M

Top Sells

Rank Stock Value
1
CVET
Covetrus, Inc. Common Stock
CVET
+$35.1M
2
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
+$16.4M
3
ARVN icon
Arvinas
ARVN
+$12.5M
4
GOSS icon
Gossamer Bio
GOSS
+$9.97M
5
OHPAU
Orion Acquisition Corp. Unit
OHPAU
+$9.87M

Sector Composition

Rank Sector Weight
1 Healthcare 97.77%
2 Consumer Staples 0.83%
3 Industrials 0.36%
4 Financials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HUM icon
1
Humana
HUM
$43.7B
$218M 5.26%
426,500
– –
IMCR icon
2
Immunocore
IMCR
$1.72B
$190M 4.56%
3,321,066
-172,677
-5% -$9.72M
PODD icon
3
Insulet
PODD
$11.5B
$154M 3.71%
524,250
+5,750
+1% +$1.59M
UNH icon
4
UnitedHealth
UNH
$376B
$143M 3.44%
270,000
+500
+0.2% +$265K
NBIX icon
5
Neurocrine Biosciences
NBIX
$16.8B
$134M 3.23%
1,122,500
– –
ARGX icon
6
argenx
ARGX
$54.6B
$133M 3.19%
350,000
– –
AGL icon
7
Agilon Health
AGL
$1.53B
$127M 3.06%
314,900
+5,000
+2% +$2.34M
RXDX
8
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$113M 2.73%
1,031,550
+386,143
+60% +$25M
PEN icon
9
Penumbra
PEN
$12.7B
$113M 2.72%
508,250
+32,250
+7% +$6.31M
EVH icon
10
Evolent Health
EVH
$348M
$107M 2.57%
3,803,500
+541,000
+17% +$15.5M
MDGL icon
11
Madrigal Pharmaceuticals
MDGL
$10.8B
$101M 2.43%
348,121
+30,636
+10% +$3M
IDXX icon
12
Idexx Laboratories
IDXX
$44.1B
$84.7M 2.04%
207,500
-16,815
-7% -$6.53M
HZNP
13
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$84.2M 2.03%
739,700
+12,700
+2% +$1.05M
AGIO icon
14
Agios Pharmaceuticals
AGIO
$1.79B
$84.1M 2.02%
2,996,592
-61,277
-2% -$1.73M
BPMC
15
DELISTED
Blueprint Medicines
BPMC
$82.9M 1.99%
1,891,510
+353,315
+23% +$16.9M
KRTX
16
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$81.3M 1.96%
413,762
– –
ISRG icon
17
Intuitive Surgical
ISRG
$127B
$79.2M 1.91%
298,500
– –
CERE
18
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$79.1M 1.9%
2,506,464
+7,316
+0.3% +$206K
ALNY icon
19
Alnylam Pharmaceuticals
ALNY
$27.5B
$79M 1.9%
332,500
– –
AKRO
20
DELISTED
Akero Therapeutics
AKRO
$76.8M 1.85%
1,400,654
+30,681
+2% +$1.31M
ACHC icon
21
Acadia Healthcare
ACHC
$2.76B
$69.6M 1.67%
845,500
+500
+0.1% +$41.2K
ALGN icon
22
Align Technology
ALGN
$12.1B
$63.8M 1.53%
302,350
-41,650
-12% -$8.34M
ACRS icon
23
Aclaris Therapeutics
ACRS
$726M
$62.4M 1.5%
3,961,249
– –
RARE icon
24
Ultragenyx Pharmaceutical
RARE
$2.45B
$59.8M 1.44%
1,290,279
+102,287
+9% +$4.02M
BAX icon
25
Baxter International
BAX
$13.5B
$58.6M 1.41%
1,150,000
+394,500
+52% +$21.2M
1
2 3 4 5

Similar funds

AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
SGI
Summit Global Investments Bountiful, Utah $1.69B AUM 12.13% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
FDP
Financiere des Professionnels Montreal, Quebec, Canada $1.71B AUM 21.77% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return

Rock Springs Capital Management's Q4 2022 Portfolio in Review

As of Q4 2022, Rock Springs Capital Management held 129 positions worth $4.16B, up 7.3% from $3.87B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Rock Springs Capital Management's Q4 2022 filing shows 1 new, 41 increased, 24 reduced and 9 closed positions. Its largest new stake was Disc Medicine: 339,497 shares worth $6.75M. The largest sale was Covetrus, Inc. Common Stock, an estimated $35.1M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Consumer Staples and Industrials.

  • Rock Springs Capital Management's largest Q4 2022 buy was Disc Medicine: 339,497 shares worth $6.75M.
  • Rock Springs Capital Management added most to Amylyx Pharmaceuticals in Q4 2022, an estimated $29.3M increase.
  • Rock Springs Capital Management's biggest Q4 2022 reduction was Shockwave Medical, Inc. Common Stock, cutting an estimated $16.4M.
  • Rock Springs Capital Management fully exited Covetrus, Inc. Common Stock in Q4 2022, selling an estimated $35.1M.
  • Rock Springs Capital Management's ten largest holdings make up 34% of its $4.16B portfolio in Q4 2022.
  • Rock Springs Capital Management opened 1 new position and closed 9 in Q4 2022.
  • Rock Springs Capital Management's portfolio value rose 7.3% quarter-over-quarter to $4.16B.

Based on Rock Springs Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.